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Abstract. Alteration and activation of recepteur d'origine 
nantais (RON) expression is known to be associated with 
cancer progression and decreased survival in various types 
of human cancer, including pancreatic cancer. Therefore, in 
the present study, RON expression levels were determined in 
resected left-sided pancreatic cancer to evaluate the poten-
tial oncological role of RON in the clinical setting of distal 
pancreatic cancer. From January 2005 to December 2011, a 
total of 57 patients underwent radical distal pancreatectomy 
for left-sided pancreatic cancer. Ductal adenocarcinoma was 
confirmed in all patients. Among these patients, 17 patients 
who received preoperative neoadjuvant treatment and 
7 patients without available paraffin‑embedded tissue blocks 
were excluded from the present study. RON expression in a 
the pancreatic cancer cell lines ASPC-1, BxPC-3, MiaPaCa-3 
and Panc-1, as well as in resected left-sided pancreatic cancer 
specimens was determined by Western blot analysis. RON and 
vascular endothelial growth factor (VEGF) overexpression 
in resected left-sided pancreatic cancer was also evaluated 
by immunohistochemistry using pre-diluted anti-RON and 
anti‑VEGF antibodies. An association was identified between 
the oncological outcome and RON overexpression. Increased 
levels of RON expression were observed in two pancreatic 
cancer cell lines, AsPC-1 and BxPC-3. RON overexpression 
was detected in specimens from 15/33 patients (45.5%) using 
immunohistochemistry. No significant association was identi-
fied between RON overexpression and VEGF overexpression 
(25.5 vs. 87.9%; P=0.667). No significant differences in 
disease‑free survival or disease‑specific survival associated 
with RON overexpression were identified. Although the results 
of previous studies have suggested that RON is a potential 
target for the treatment of pancreatic cancer, in the present 
study no association between RON overexpression and any 
adverse oncological effect was identified.
Introduction
Recepteur d'origine nantais (RON), a receptor tyrosine kinase 
belonging to the MET proto-oncogene family (1) shares ~60% 
structural homology with the c-MET receptor (2). RON is 
synthesized as a single-chain precursor, pro-RON, which is 
then cleaved into a 40-kDa α-chain and a 150-kDa β-chain (3). 
A single disulfide bond links these two chains to form a 
180-kDa heterodimer. The α-chain is completely extracellular, 
and the β-chain has extracellular, transmembrane and intracel-
lular regions containing a functional tyrosine kinase segment 
as well as multiple regulatory elements. The ligand for RON 
is macrophage-stimulating factor, also known as hepatocyte 
growth factor-like protein or scatter factor-2 (4).
Altered RON expression and activation are known to be 
associated with cancer progression and decreased survival 
in a number of types of human cancer, including breast (5), 
colon (6), gastric (7), non-small cell lung (8), bladder (9) and 
ovary (10) cancer. Research into RON in pancreatic cancer is a 
relatively recent development. The currently available evidence 
to support the potential role of RON in carcinogenesis of 
pancreatic cancer and implications for future targeted therapy 
in treating pancreatic cancer was previously reviewed (11). RON 
has been demonstrated to serve important roles in pancreatic 
cancer carcinogenesis (12-14), epithelial-mesenchymal tran-
sition (15,16), tumor migration (17-19), angiogenesis (20,21), 
cancer stem cells (22) and apoptotic resistance (14,23,24) as 
a part of the progression of pancreatic cancer, suggesting that 
RON may be a potential therapeutic target in the treatment of 
pancreatic cancer. In particular, RON signaling was previously 
identified to increase VEGF level and promote microtubule 
formation in BxPC-3 and FG cells, suggesting an specific 
mechanism for the association of RON with pancreatic cancer 
progression (21).
Chakedis et al (25,26) identified a novel RON isoform 
in human pancreatic cancer. Partial splicing of exons 5 and 
6 (P5P6) produces a RON isoform that lacks the first extra-
cellular immunoglobulin-plexin-transcription domain (25); 
RNA sequencing studies revealed that the P5P6 isoform has 
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ligand-independent activity and induces markedly different 
patterns of gene expression when compared with wild type 
RON, providing further understanding of RON biology in 
pancreatic cancer carcinogenesis and exhibiting potential 
implications for therapeutic strategy (26). RON-specific 
therapeutic approaches, including tyrosine kinase inhibitors 
and monoclonal antibodies, have been tested in preclinical and 
clinical trials to determine their anti‑cancer efficacy (27‑29). 
However, their therapeutic efficacy was relatively low. Great 
effort has since been made to increase the efficacy of mono-
clonal antibodies against RON for the treatment of pancreatic 
cancer (30).
However, the data indicating potential associations between 
RON expression and the clinical outcome of pancreatic cancer 
are presently limited. Unless this association is confirmed, the 
recent drive into RON research may be attenuated. Therefore, 
in the present study, the association between VEGF expression 
and clinical outcomes with RON expression was evaluated 
in resected left-sided pancreatic cancer, in order to assess 
the potential role of RON in the clinical setting of left-sided 
pancreatic cancer.
Materials and methods
Patient enrollment and review of medical records. From 
January 2005 to December 2011, a total of 57 patients 
underwent radical distal pancreatosplenectomy for left-sided 
pancreatic cancer at Severance hospital, Yonsei University 
College of Medicine (Seoul, Korea). Ductal adenocarcinoma 
was confirmed in all patients. A total of 17 patients who 
received preoperative neoadjuvant treatment and 7 patients 
for whom paraffin-embedded tissue blocks were unavail-
able were excluded (Fig. 1). The patients' clinicopathological 
characteristics, including age, sex, clinical presentation, tumor 
size, histopathological features and follow-up data were 
reviewed and recorded. The present study was approved by 
the Institutional Review Board of Yonsei University College 
of Medicine.
Cell lines and cell maintenance. The human pancreatic cancer 
cell lines ASPC-1, BxPC-3, MiaPaCa-2 and Panc-1 were 
obtained from the Bioevaluation Center (Korea Research 
Institute of Bioscience and Biotechnology, Daejeon, Korea). 
ASPC-1 and BxPC-3 cells were maintained in RPMI medium, 
Panc‑1 cells were maintained in Dulbecco's modified Eagle's 
medium and MiaPaCa-2 cells were maintained in minimal 
essential medium. All tissue culture media were from Gibco 
(Thermo Fisher Scientific, Inc.), and were supplemented with 
10% fetal bovine serum and 1% penicillin-streptomycin, unless 
otherwise noted. All cells were grown at 37˚C in a humidified 
incubator containing CO2.
Western blot analysis. Harvested cells were lysed in cell 
extraction buffer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 
2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS 
and 0.5% deoxycholate). A 40 µg amount of total protein, as 
quantified with a Bradford assay, was treated with Laemmli 
sample buffer (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA), heated at 100˚C for 5 min and then resolved by 8% 
SDS-PAGE. Gels were electroblotted onto nitrocellulose 
membranes (GE Healthcare Life Sciences, Chalfont, UK). 
Membranes were blocked with 5% non-fat dry milk in 
Tris-buffered saline with Tween-20, incubated with antibodies 
against total RON (cat. no., ab52927; Abcam, Cambridge, 
UK) and β-actin (cat. no., ab8227; Sigma-Alrich; Merck 
KGaA, Darmstadt, Germany) overnight at 4˚C, and then 
probed with secondary antibodies (horseradish peroxidase 
conjugated mouse anti-rabbit IgG; cat. no., sc2357; Santa 
Cruz Biotechnology, Inc., Dallas, TX, USA) for 1 h at room 
temperature. All antibodies were treated with Dako Antibody 
Diluent (Agilent Technologies, Santa Clara, CA, USA). The 
washes were repeated and the membrane was developed using 
a chemiluminescent agent (GE Healthcare Life Sciences). The 
whole process was performed in triplicate.
Immunohistochemistry. Formalin‑fixed paraffin‑embedded 
tissue sections (4 µm) thick were deparaffinized and rehydrated 
prior to antigen retrieval. Deparaffinization was performed on 
a rack with the following washes: Xylene for 3 min, xylene 1:1 
with 100% ethanol for 3 min, 100% ethanol for 3 min, 95% 
ethanol for 3 min, 70% ethanol for 3 min, 50% ethanol with 
3 min, then a final rinse with tapwater. Immunohistochemical 
analysis was performed using pre-diluted anti-RON (cat. 
no., ab52927; Abcam) and anti-vascular endothelial growth 
factor (VEGF; cat. no., sc-152; Santa Cruz Biotechnology, Inc.) 
antibodies, according to the manufacturer's protocol. All slides 
were reviewed by two pathologists blinded to the oncological 
outcomes and clinicopathological variables. The intensities of 
RON and VEGF were scored as 0, null; 1+, positive; and 2+, 
strong positive.
Statistical analysis. Statistical analysis was performed 
using SPSS 23 software (IBM SPSS, Armonk, NY, USA). 
Continuous variables are presented as the mean ± standard 
deviation and categorical variables are expressed as the 
frequency (%). Univariate analysis was performed using a χ2 
test, and Student's t-test was used for statistical assessment of 
the association between clinicopathological characteristics 
and RON overexpression. Survival curves were obtained by 
the Kaplan-Meier method, and differences in survival between 
groups were compared with the log rank test. P<0.05 was 
considered to indicate a statistically significant difference.
Results
RON expression in pancreatic cancer cell lines and resected 
left‑sided pancreatic cancer. RON protein expression was 
determined by Western blot analysis in pancreatic cancer cell 
lines (Fig. 2). All cell lines evaluated expressed RON at various 
levels. In particular, AsPC‑1 and BxPC‑3 were identified to 
exhibit increased expression of both the RON α- and β-chains. 
By contrast, MiaPaCa‑2 and Panc‑1 cells were identified to 
exhibited relatively decreased levels of RON expression. In 
immunohistochemistry studies, 15/33 patients (45.5%) with 
resected left‑sided pancreatic cancer were identified to overex-
press RON (Fig. 3A and b).
RON and VEGF overexpression in resected left‑sided pancre‑
atic cancer. Specimens from 29 patients (87.9%) exhibited 
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VEGF overexpression (Fig. 3C and d). No association between 
RON and VEGF expression was identified in resected left‑sided 
pancreatic cancer (P=0.381; Table I).
Clinical validation of the oncological role of RON expres‑
sion in resected left‑sided pancreatic cancer. No association 
between clinical oncological parameters and overexpression in 
resected left‑sided pancreatic cancer was identified (P>0.05; 
Table II). In particular, no significant differences in tumor 
stage (P=0.981), tumor size (P=0.2000), node stage (P=0.898), 
perineural invasion (P=1.000) and lymphovascular invasion 
(P=0.919) were identified.
In addition, RON overexpression did not cause any 
oncological effect on tumor recurrence and overall survival. 
In resected left‑sided pancreatic cancer, no significant differ-
ences in disease-free survival (median, 12.8 months [95% CI 
(confidence interval), 0‑45.1] vs. median, 25.3 months (95% CI, 
0‑67.4); P=0.272; Fig. 4A) or disease‑specific survival [median, 
43.8 months (95% CI, 16.6-70.9) vs. median, 42.7 months (95% 
CI, 22‑63.3); P=0.899; Fig. 4B] between RON‑positive and 
RON‑negative patients were identified.
Discussion
A previous study has suggested a potential oncological role 
for RON expression in pancreatic cancer progression (10); 
however, there have been limited studies concerning the onco-
logical effect of RON overexpression in resected pancreatic 
cancer. To the best of our knowledge, only a single study has 
been published: Tactacan et al (31) assessed RON expression 
in a total of 492 pancreatic cancer patients and evaluated the 
association between RON expression and patient outcomes 
and clinicopathological variables. The study identified that 
increased RON expression was a biomarker for poor prognosis 
in a training set. However, the study failed to identify that 
RON expression was not prognostic in the larger validation 
set. In addition, no association was identified between RON 
expression and tumor stage (P=0.123), tumor size (P=0.629) 
lymph node metastases (P=0.942), grade (P=0.332), perineural 
invasion (P= 0.335) or vascular invasion (P=0.210), leading 
to the conclusion that RON is not a prognostic marker for 
resectable pancreatic cancer. When looking at their patient 
population, >80% of the patients had pancreatic head cancer, 
therefore allowing the possibility of unintended contamination 
by other periampullary cancers from the ampulla of Vater and 
distal bile ducts. To avoid this potential selection bias in the 
present study, the study population consisted only of patients 
with resected left-sided pancreatic cancer.
Thomas et al (21) demonstrated that RON signaling resulted 
in mitogen-activated protein kinase-mediated VEGF secretion 
by pancreatic cancer cells and in the promotion of microtubule 
Figure 1. Patient eligibility. From January 2005 to December 2011, a total of 57 patients underwent radical distal pancreatosplenectomy for left-sided pancre-
atic cancer with histological confirmation of ductal adenocarcinoma. Among these patients, 17 patients who received preoperative neoadjuvant treatment and 
7 patients for whom paraffin‑embedded tissue blocks were unavailable were excluded from the present study.
Figure 2. Western blot analysis of RON α- and β-chain expression in pancre-
atic cancer cell lines. The levels of RON protein were determined by Western 
blot analysis in pancreatic cancer cell lines. AsPC-1 and BxPC-3 exhib-
ited increased levels of expression of the RON α- and β-chains. However, 
MiaPaCa-2 and Panc-1 exhibited relatively decreased levels of RON expres-
sion. RON, recepteur d'origine nantais.
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formation, suggesting that RON signaling may also positively 
regulate an angiogenic mediator, VEGF, to promote cancer 
progression in pancreatic cancer. This may explain the results 
of another study where treatment with gemcitabine plus the 
anti-VEGF monoclonal antibody bevacizumab failed to 
provide an oncological benefit over gemcitabine treatment 
alone (32). However, in the present study, no association 
between RON and VEGF expression in resected left-sided 
pancreatic cancer was identified (P=0.381). Our understanding 
of the regulation of angiogenesis in pancreatic cancer therefore 
remains limited.
The clinical data of the present study also failed to reveal 
an oncological role for RON in resected left-sided pancreatic 
cancer. Following assessment of the potential association of 
RON expression with clinicopathological characteristics, 
RON overexpression was not identified to be associated with 
tumor size, pathological node stage, pathological tumor stage, 
tumor differentiation, perineural invasion or lymphovascular 
invasion (P>0.05). In addition, there were no significant onco-
logical differences in terms of disease‑free and disease‑specific 
survival.
There are a number of potential reasons for the current 
missing link between RON expression and oncological 
outcome in resected left-sided pancreatic cancer, as follows: 
i) Pancreatic cancer harbors multiple genetic mutations and 
various dysregulated signaling pathways the contribute to 
cancer progression. ii) It is known that there are multiple 
splice variants of the RON receptor (33-35), including RON 
Δ165, RON Δ160, RON Δ155, RON Δ170, RON Δ110 and 
RON Δ52. To the best of our knowledge, the presence of 
these variant types of the RON receptor has not been investi-
gated, and their individual oncogenic capability has not been 
evaluated in pancreatic cancer. In addition, it is impossible 
to discriminate between these variant types of RON recep-
tors using current immunohistochemistry techniques. In 
particular, a truncated form of the RON receptor (short-form 
RON), lacking a majority of the extracellular domain (36), 
may not be detectable by conventional routine immunohis-
tochemistry. However, this short-form RON is constitutively 
active, leading to pathogenesis and cancer progression in 
pancreatic cancer. iii) The potential role of the microenvi-
ronment also requires consideration. It is well-known that 
severe fibrosis and a desmoplastic reaction including fibro-
blasts, immune cells, endothelial cells and neural cells are 
associated with pancreatic cancer. Evidence from a previous 
study suggests that interactions occur between the microen-
vironment and pancreatic cancer cells, facilitating pancreatic 
cancer pathogenesis (37). It was not possible to replicate the 
potential contribution of this 'harmony' in the present study. 
iv) Finally, the present study was based on a retrospective 
study design with a small number of patients. Therefore, 
selection bias was unavoidable.
RON overexpression failed to result in an adverse 
oncological effect in resected left-sided pancreatic cancer, 
despite previous studies suggesting that RON may be a 
Table II. Association between RON overexpression and 
clinical oncological parameters.
 RON overexpression
Oncological ---------------------------------------------------------
parameter No Yes P-value
CA19-9, 
U/ml ± SD 1304.7±4671.5 603.3±1475.6 0.581
Tumor size, 
cm ± SD 3.1±0.9 2.7±0.9 0.200
T stage   0.981
  T1 0 0 
  T2 1 1 
  T3 16 13 
  T4 1 1 
N stage   0.898
  N0 8 7 
  N1 10 8 
LNR 0.4±1.3 0.1±0.1 0.384
Differentiation   0.750
  Well 4 3 
  Moderate 11 11 
  Poor 2 1 
  None 1 0 
LVI   0.919
  No 10 9 
  Yes 6 5 
PNI   1.000
  No 8 7 
  Yes 8 7 
R-status   0.727
  R0 16 12 
  R1 1  
  R2 1 1 
Postadjuvant 
chemotherapy   0.475
  No 4 5 
  Yes 14 10 
RON, recepteur d'origine nantais; CA19-9, cancer antigen 19-9; 
SD, standard deviation; T, tumor; N, node; LNR, lymph node ratio; 
LVI, lymphovascular invasion; PNI, perineural invasion; R, residual 
tumor.
Table I. Association between RON and VEGF overexpression.
 RON 
 overexpression
 ----------------------------
Parameter  0 1+ P-value
VEGF 0 3 1 0.381
overexpression 1+ 8 8
 2+ 7 6
RON, recepteur d'origine nantais; VEGF, vascular endothelial 
growth factor.
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potential target in the treatment of pancreatic cancer. 
Further clinical studies validating the potential oncological 
role of RON are required, and consideration of the multifac-
torial and heterogeneous nature of pancreatic cancer is also 
required.
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Figure 4. Oncological effect of RON expression in resected left‑sided pancreatic cancer. (a) No significant difference in disease‑free survival was identified 
between RON‑positive patients and RON‑negative patients (median, 12.8 months vs. 25.3 months; P=0.272). (b) No significant difference in disease‑specific 
survival was identified between RON‑positive patients and RON‑negative patients (median, 43.8 months vs. 42.7 months; P=0.899). RON, recepteur d'origine 
nantais.
Figure 3. Immunohistochemical staining for RON and VEGF expression in resected pancreatic cancer. (a) RON-negative control. (b) RON-positive. Samples 
from 15/33 patients (45.5%) exhibited RON overexpression by immunohistochemical staining. (c) VEGF 1+. (d) VEGF 2+. A total of 29 patients (87.9%) were 
determined to exhibit VEGF overexpression. No association between RON overexpression and VEGF overexpression was identified. RON, recepteur d'origine 
nantais; VEGF, vascular endothelial growth factor.
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